BSE Live
Mar 13, 16:01Prev. Close
62.76
Open Price
61.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 13, 15:59Prev. Close
62.18
Open Price
61.01
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
58.17 (590)
| Balance Sheet of Brooks Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | |
| 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||||
| SHAREHOLDER'S FUNDS | |||||
| Equity Share Capital | 4.65 | 2.58 | 0.63 | 0.63 | |
| Total Share Capital | 4.65 | 2.58 | 0.63 | 0.63 | |
| Reserves and Surplus | 8.89 | 5.77 | 4.71 | 1.12 | |
| Total Reserves and Surplus | 8.89 | 5.77 | 4.71 | 1.12 | |
| Total Shareholders Funds | 13.54 | 8.35 | 5.34 | 1.76 | |
| NON-CURRENT LIABILITIES | |||||
| Long Term Borrowings | 11.82 | 16.06 | 12.35 | 8.04 | |
| Deferred Tax Liabilities [Net] | 0.86 | 0.69 | 0.48 | 0.26 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 12.68 | 16.75 | 12.83 | 8.31 | |
| CURRENT LIABILITIES | |||||
| Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade Payables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Current Liabilities | 10.05 | 6.51 | 7.18 | 4.73 | |
| Short Term Provisions | 0.99 | 0.41 | 0.55 | 0.18 | |
| Total Current Liabilities | 11.04 | 6.92 | 7.73 | 4.91 | |
| Total Capital And Liabilities | 37.30 | 32.05 | 25.89 | 14.98 | |
| ASSETS | |||||
| NON-CURRENT ASSETS | |||||
| Tangible Assets | 19.38 | 17.05 | 9.30 | 8.44 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.02 | 0.06 | 0.00 | 0.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 19.40 | 17.12 | 9.30 | 8.44 | |
| Non-Current Investments | 0.02 | 0.02 | 0.00 | 0.00 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.01 | 0.02 | 0.03 | 0.03 | |
| Total Non-Current Assets | 19.43 | 17.16 | 9.32 | 8.47 | |
| CURRENT ASSETS | |||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 4.73 | 3.47 | 4.70 | 1.93 | |
| Trade Receivables | 8.56 | 7.17 | 4.06 | 2.43 | |
| Cash And Cash Equivalents | 0.86 | 2.20 | 5.23 | 0.15 | |
| Short Term Loans And Advances | 3.73 | 2.06 | 2.59 | 2.00 | |
| OtherCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 17.87 | 14.90 | 16.57 | 6.51 | |
| Total Assets | 37.30 | 32.05 | 25.89 | 14.98 | |
| OTHER ADDITIONAL INFORMATION | |||||
| CONTINGENT LIABILITIES, COMMITMENTS | |||||
| Contingent Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | |
| CIF VALUE OF IMPORTS | |||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||||
| Expenditure In Foreign Currency | 0.00 | 0.00 | 0.00 | 0.00 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | |||||
| FOB Value Of Goods | -- | -- | -- | -- | |
| Other Earnings | -- | -- | -- | -- | |
| BONUS DETAILS | |||||
| Bonus Equity Share Capital | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | |||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 0.02 | 0.02 | -- | -- | |
| CURRENT INVESTMENTS | |||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- |
18.02.2026
Brooks Labs Consolidated December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
10.02.2026
Brooks Labs Standalone December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
04.12.2025
Brooks Labs Consolidated September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
27.11.2025
Brooks Labs Standalone September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
18.02.2026
Brooks Labs Consolidated December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
10.02.2026
Brooks Labs Standalone December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
04.12.2025
Brooks Labs Consolidated September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
27.11.2025
Brooks Labs Standalone September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
15.03.2026
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth